FOLLOW US
J. Michael   Gonzalez-Campoy, MD, PhD, FACE's portrait

J. Michael Gonzalez-Campoy, MD, PhD, FACE

Medical Director and Chief Executive Officer
Minnesota Center for Obesity, Metabolism and Endocrinology
Eagan, MN

About J. Michael Gonzalez-Campoy, MD, PhD, FACE

J. Michael Gonzalez-Campoy, MD, PhD, FACE, is Medical Director and Chief Executive Officer of the Minnesota Center for Obesity, Metabolism and Endocrinology in Eagan, Minnesota.

Dr. Gonzalez-Campoy earned his medical degree and PhD in physiology and biophysics from the Mayo Medical School and Mayo Graduate School in Rochester, Minnesota. He received a fellowship in diabetes, endocrinology, and metabolism from the University of Minnesota. His clinical and research interests include the prevention and treatment of obesity and adiposopathy, and their complications.

Dr. Gonzalez-Campoy lectures nationally and internationally and has chaired or been an invited speaker for several national meetings on obesity and adiposopathy. He is past member of the American College of Endocrinology Board of Trustees and the American Association of Clinical Endocrinologists Board of Directors. Dr. Gonzalez supported the launch of the Association of Clinical Researchers and Educators (ACRE), which is dedicated to highlight the value of collaborative relationships between physicians and industry.

Articles Written by J. Michael Gonzalez-Campoy, MD, PhD, FACE

Body Fat and Diabetes: BMI Cut-off for Asian Americans

Mounting evidence has shown Asian Americans are being diagnosed with diabetes at BMIs lower than the standard cut-offs for being overweight or obese.
The American Diabetes Association (ADA) has lowered the Body Mass Index (BMI) cut-off for Asian Americans at risk of developing Type 2 diabetes.

Exercise Can Reduce Risk of Diabetes in Women With Gestational Diabetes

A new study shows that regular exercise can reduce a woman's risk of developing type 2 diabetes after she has had gestational diabetes.

Exercise Lowers Risk for Type 2 Diabetes in Women With a History of Gestational Diabetes

Gestational diabetes put women at risk of developing type 2 diabetes later in life. Exercise may help mitigate that risk.

New GLP-1 Approved for Type 2 Diabetes

Tanzeum (albiglutide) is the third GLP-1 approved by the Food and Drug Administration.
There are an estimated 26 million people with diabetes in the United States, and two-thirds of them are overweight or obese.

Articles Reviewed by J. Michael Gonzalez-Campoy, MD, PhD, FACE

A Breath Test for Ketoacidosis

British investigators are researching a non-invasive breath test to quickly diagnose diabetic ketoacidosis.
Type 1 diabetes: Researcher are developing a non-invasive breath test to diagnose diabetic ketoacidosis.

Rates of New Cases of Diabetes Slowing

New study may signal a ‘slowing of the diabetes epidemic,’but minorities and the young still at higher risk.
Diabetes is a serious health problem in the United States, as more Americans are diagnosed every day.

Financial Disclosures for J. Michael Gonzalez-Campoy, MD, PhD, FACE

OnTrack Diabetes, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, OnTrack Diabetes requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

Author's Statement

I, or an immediate family member, have a financial interest(s) or affiliation(s) with the following commercial companies whose products and / or services may be mentioned in the materials I have authored, edited or reviewed for presentation on Vertical Health, LLC’s websites.

Disclosed Relationships

Speakers' Bureau
Janssen
MAIN MENU